Viatris

VTRS

Canonsburg, United States· Est. 2020

viatris.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

VTRS · Stock Price

USD 17.39+8.62 (+98.29%)

Market Cap: $20.1B

Historical price data

Market Cap: $20.1BPipeline: 200 drugs (41 Phase 3)Founded: 2020Employees: ~38,000-45,000HQ: Canonsburg, United States

Sector Ranking#89 in Small Molecule Drugs #62 in Biologics / Biosimilars

Overview

Viatris is a mission-driven global healthcare company formed in 2020 to empower people worldwide to live healthier lives through expanded access to medicines. Its strategy is built on four complementary pillars—generics, complex generics, biosimilars, and established brands—enabling it to deliver a broad portfolio across therapeutic areas and economic spectrums. The company has established itself as a leader in biosimilars and complex generics, managing a significant pipeline of 247 candidates while executing a strategic transformation to optimize its portfolio and drive sustainable growth through 2030.

CardiologyDermatologyImmunologyInfectious DiseasesCentral Nervous System DisordersOncologyRespiratory

Technology Platform

An integrated Global Healthcare Enablement Platform combining deep expertise in complex generics formulation, biosimilar development, global regulatory strategy, and a resilient, diversified supply chain to deliver accessible medicines at scale.

Pipeline

200

200 drugs in pipeline41 in Phase 3

Drug	Indication	Stage
MYL-1601D Product + FlexPen NovoLog®	Diabetes Mellitus, Type 1	Phase 3
Cenerimod + Placebo	Nephritis, Lupus	Phase 3
MYL-1401A (Adalimumab) + Humira® (Adalimumab)	Psoriasis	Phase 3
Thioctic Acid + Placebo	Diabetic Polyneuropathy	Phase 3
MR-100A-01	Contraception	Phase 3

FDA Approved Drugs

ERMEZANDAApr 29, 2022

PRETOMANIDNDAAug 14, 2019

YUPELRINDANov 9, 2018

Opportunities

Viatris is poised to capitalize on the massive upcoming patent cliff for biologics and complex drugs, leveraging its expertise in biosimilars and complex generics.

Furthermore, global healthcare systems' increasing focus on cost containment and supply chain resilience plays directly to its strengths in providing affordable, reliable medicines at scale.

Risk Factors

The company faces persistent pricing erosion in the core generics market, particularly in the U.S., and must successfully execute its strategic transformation plan to transition from stability to growth.

Regulatory hurdles and delays for key complex pipeline products, along with macroeconomic volatility, also pose significant risks.

Competitive Landscape

Viatris competes with large generic firms (Teva, Sandoz) in complex generics, with dedicated biosimilar players (Amgen, Celltrion), and with large pharma on established brands. Its primary competitive moat is its integrated global platform for developing, manufacturing, and commercializing high-barrier-to-entry complex products across a vast geographic footprint.